Androgen Deprivation Therapy May Raise Dementia Risk

Share this content:
Androgen Deprivation Therapy May Raise Dementia Risk
Androgen Deprivation Therapy May Raise Dementia Risk

FRIDAY, Oct. 14, 2016 (HealthDay News) -- The risk of dementia might be doubled for prostate cancer patients who are treated with androgen-deprivation therapy (ADT), according to a study published online Oct. 13 in JAMA Oncology.

Kevin Nead, M.D., a radiation oncology resident at the University of Pennsylvania in Philadelphia, who conducted the research while at Stanford University in California, and colleagues analyzed data for 9,272 men with prostate cancer. Of those men, 1,826 received ADT.

The researchers discovered that men who received ADT were more likely to be diagnosed with dementia during a five-year follow-up period. Men who underwent ADT had a 7.9 percent risk of developing dementia within five years of treatment, compared with a 3.5 percent risk for prostate cancer patients who didn't receive the therapy.

"Androgen deprivation therapy in the treatment of prostate cancer may be associated with an increased risk of dementia," the authors write. "Our study extends previous work supporting an association between use of ADT and Alzheimer's disease and suggests that ADT may more broadly affect neurocognitive function. This finding should be further evaluated in prospective studies."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Florida Teen First Human Case of Another Mosquito-Borne Virus

Florida Teen First Human Case of Another Mosquito-Borne ...

First documented case of Keystone infection in a human

70 Sickened So Far in Salmonella-Tainted Melon Outbreak

70 Sickened So Far in Salmonella-Tainted Melon Outbreak

Illnesses reported in Illinois, Indiana, Kentucky, Michigan, Missouri, Ohio, and Tennessee

AAFP Still Recommends CRC Screening From Age 50 to 75

AAFP Still Recommends CRC Screening From Age 50 ...

Despite ACS change to start screening from age 45 years, AAFP agrees with USPSTF recommendation

is free, fast, and customized just for you!




Already a member?

Sign In Now »